Objective To investigate the expression of non-receptor protein tyrosine phosphatase 18(PT-PN18)and RNA binding protein FOX2(RBFOX2)in endometrial cancer(EC),and to analyze their relation-ship with clinicopathological features and prognostic significance.Methods A total of 122 EC patients treated in Hainan Women and Children's Medical Center from January 2020 to June 2021 were collected.The expres-sion of PTPN18 and RBFOX2 protein was detected by immunohistochemistry.The expressions of PTPN18 mRNA and RBFOX2 mRNA were detected by real-time fluorescence quantitative PCR.Pearson correlation a-nalysis was used to analyze the correlation between PTPN18 mRNA and RBFOX2 mRNA expression in EC.Kaplan-Meier curve and multivariate Cox regression model were used to analyze the effect of PTPN18 mRNA and RBFOX2 mRNA expression on the prognosis of EC patients.Results Compared with adjacent tissues,PTPN18 protein expression(2.53±0.67 vs.0.56±0.14)was higher and RBFOX2 protein expression(0.74±0.22 vs.3.11±0.63)was lower in EC cancer tissues,and the difference was statistically significant(t=31.790,39.229,P<0.001).Compared with adjacent tissues,PTPN18 mRNA expression(3.15±0.76 vs.0.78±0.23)was higher and RBFOX2 mRNA expression(1.14±0.34 vs.3.87±0.80)was lower in EC cancer tissues,and the difference was statistically significant(t=32.976,34.689,P<0.001).There was a negative correlation between the expression of PTPN18 mRNA and RBFOX2 mRNA in EC(r=-0.674,P<0.001).The expression of PTPN18 mRNA was higher and RBFOX2 mRNA was lower in FIGO stage Ⅲ EC patients with lymph node metastasis(P<0.05).There was no significant difference in 3-year overall survival rate between PTPN18 mRNA high expression group and low expression group,and between RBFOX2 mRNA high expression group and low expression group(P>0.05).The 3-year progression-free survival rate of the PTPN18 mRNA high expression group was lower than that of the low expression group,and the 3-year pro-gression-free survival rate of the RBFOX2 mRNA high expression group was higher than that of the low ex-pression group,and the differences were statistically significant(P<0.001).FIGO stage Ⅲ,lymph node me-tastasis and PTPN18 mRNA were risk factors for progression-free survival in EC patients,and RBFOX2 mR-NA was a protective factor(P<0.05).Conclusion PTPN18 expression is increased and RBFOX2 expression is decreased in EC,which is related to FIGO stage and lymph node metastasis.PTPN18 is a tumor marker for evaluating the prognosis of EC.

Objective]To explore the aberrant expression of SOD1 gene in nasopharyngeal carcinoma tissues and adjacent tissues,as well as in NPC cell lines,then to observe the effect of SOD1 on NPC cells metastatic ability and investigate the intrinsic?mechanism.[Methods]Immunohistochemical technique was used to examine SOD1 expression in carcinoma tissues and adjacent tissues(n=10). Small interfering RNAs and inhibitor LCS-1 were used to knockdown of SOD1 expression and inhibit SOD1 activity, respectively. Then,wound healing test and migration assay were applied to detect cell metastatic ability in vitro. Real-time PCR and Western Blot were used to analyze the expression of EMT-related genes(E-cadherin,Vimentin,Twist).[Results]SOD1 was found to be significantly up-regulated in nasopharyngeal carcinoma tissues(n = 7 ,70%),compared to control. SOD1 was also highly expressed in highly metastatic potential NPC cell lines(CNE2,5-8F,S18)compared with low metastatic ability cell lines(6-10B). Knockdown SOD1 expression or inhibit SOD1 activity suppress cell motility in CNE2 and 5-8F cells. Finally,we demonstrate that SOD1 inhibition plays a role in induction of epithelial marker E-cadherin and has an opposite effect on mesenchymal marker vimen tin and transcriptional factor twist.[Conclusion]These results suggest that SOD1 contributes to EMT and might be important for tumor metastasis in NPC.